NeuroSAFE remains an investigational, debatable, laborious (expensive) procedure

patients later, then perhaps we could be less concerned. However, we do not. Further, a holistic clinical judgement as to whether investigation or treatment is to be of benefit for any patient is best. This is especially true in the age group 70–79 years. Tradition dictates these patients are too old to benefit from curative treatment. However, many of these patients remain in good health and have more than a decade of life expectancy.